Purpose Voriconazole, an antifungal drug, is metabolized by a cytochrome P450 isozyme.
Increased adverse effects are observed in Asians because of the high rate of poor …

Second generation triazoles are widely used as first-line drugs for the treatment of invasive
fungal infections, including aspergillosis and candidiasis. This class, along with …

The administration of antifungals for therapeutic and, especially, prophylactic purposes is
virtually a constant in patients requiring hematology-oncology treatment. Any attempt to …

ABSTRACT Voriconazole (VRC), a first-line agent for the treatment of invasive fungal
infections, is mainly metabolized by human cytochrome P450 (CYP) 2C19. In this study, a …

The development of Pharmacogenetics and Pharmacogenomics in Western Europe is
highly relevant in the worldwide scenario. Despite the usually low institutional support, many …

Background: Voriconazole plasma concentration exhibits significant variability and
maintaining it within the therapeutic range is the key to enhancing its efficacy. We conducted …

Aims: We aimed to assess the impact of extracorporeal membrane oxygenation (ECMO) on
voriconazole exposure. Methods: Adult critically ill patients with or without ECMO support …

Voriconazole is a triazole antifungal agent commonly used for the treatment and prevention
of invasive aspergillosis (IA). However, the study of voriconazole's use in children is limited …

This prospective observational study aimed to clinically describe voriconazole
administrations and trough concentrations in patients with Child–Pugh class C and to …

Aims: To explore the interactive influence of glucocorticoids and cytochrome P450 (CYP450)
polymorphisms on voriconazole (VRC) plasma trough concentrations (Cmin) and provide a …